^
    Apply
    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) (NCT04939610)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    07/30/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2028
    FAP
    |
    FAP expression
    |
    AAA614
    Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers (NCT04171219)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/19/2020
    Primary completion :
    12/30/2025
    Completion :
    12/30/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • talabostat (BXCL701)
    Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment (BP42675) (NCT04826003)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    07/14/2021
    Primary completion :
    12/27/2024
    Completion :
    12/27/2024
    CEACAM5
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)
    Evaluatioon of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors (NCT05410743)
    Phase 1
    The First Affiliated Hospital of Xiamen University
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    06/01/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    SSTR • FAP
    |
    SSTR positive • SSTR Expression
    |
    177Lu-LNC1010
    An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma (NCT05518903)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    11/21/2023
    Initiation :
    11/15/2022
    Primary completion :
    06/30/2027
    Completion :
    06/30/2028
    KRAS • CA 19-9
    A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma (NCT03875079)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/29/2023
    Initiation :
    06/24/2019
    Primary completion :
    07/14/2022
    Completion :
    07/14/2022
    PD-L1 • BRAF • CD8 • FOXP3
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • simlukafusp alfa (RG7461)
    Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) (NCT03063762)
    Phase 1b
    Hoffmann-La Roche
    Completed
    Last update posted :
    02/17/2023
    Initiation :
    03/20/2017
    Primary completion :
    06/14/2021
    Completion :
    06/14/2021
    PD-L1
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • simlukafusp alfa (RG7461)
    Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors (NCT04049903)
    Phase 1
    Molecular Partners AG
    Completed
    Last update posted :
    12/22/2022
    Initiation :
    09/02/2019
    Primary completion :
    06/27/2022
    Completion :
    12/21/2022
    MSI
    |
    MSI-H/dMMR
    |
    MP0310
    A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (NCT02627274)
    Phase 1a/1b
    Hoffmann-La Roche
    Completed
    Last update posted :
    11/22/2022
    Initiation :
    12/07/2015
    Primary completion :
    11/10/2022
    Completion :
    11/10/2022
    CD20
    |
    EGFR positive
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • simlukafusp alfa (RG7461)
    A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02558140)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    04/04/2018
    Initiation :
    10/11/2015
    Primary completion :
    11/06/2017
    Completion :
    11/06/2017
    FAP
    |
    FAP expression
    Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) (NCT00086203)
    Phase 2
    Point Therapeutics
    Completed
    Last update posted :
    03/25/2015
    Completion :
    09/01/2007
    CD20
    |
    CD20 expression
    |
    Rituxan (rituximab) • talabostat (BXCL701)